GT200600263A - Regimen de dosificacion para prasugrel - Google Patents

Regimen de dosificacion para prasugrel

Info

Publication number
GT200600263A
GT200600263A GT200600263A GT200600263A GT200600263A GT 200600263 A GT200600263 A GT 200600263A GT 200600263 A GT200600263 A GT 200600263A GT 200600263 A GT200600263 A GT 200600263A GT 200600263 A GT200600263 A GT 200600263A
Authority
GT
Guatemala
Prior art keywords
dosage regime
prasugrel
approximately
dosage
same
Prior art date
Application number
GT200600263A
Other languages
English (en)
Spanish (es)
Inventor
John Thomas Brandt
Nagy Alphonse Farid
Joseph Anthony Jakubowski
Christopher David Paybe
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT200600263A publication Critical patent/GT200600263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GT200600263A 2005-06-17 2006-06-16 Regimen de dosificacion para prasugrel GT200600263A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
GT200600263A true GT200600263A (es) 2007-02-23

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600263A GT200600263A (es) 2005-06-17 2006-06-16 Regimen de dosificacion para prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (https=)
EP (1) EP1893205A4 (https=)
JP (1) JP2008543853A (https=)
KR (1) KR20080016647A (https=)
CN (1) CN101198329A (https=)
AU (1) AU2006259538A1 (https=)
BR (1) BRPI0612624A2 (https=)
CA (1) CA2612315A1 (https=)
EA (1) EA200800075A1 (https=)
EC (1) ECSP078014A (https=)
GT (1) GT200600263A (https=)
IL (1) IL187486A0 (https=)
MA (1) MA29722B1 (https=)
MX (1) MX2007015430A (https=)
NO (1) NO20080244L (https=)
TN (1) TNSN07474A1 (https=)
WO (1) WO2006138317A2 (https=)
ZA (1) ZA200710769B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5274261B2 (ja) 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
EP2100607A4 (en) * 2006-12-07 2010-01-06 Daiichi Sankyo Co Ltd COATING COMPOSITION WITH IMPROVED DURABILITY
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
WO2010132711A1 (en) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
ATE398624T1 (de) * 2000-07-06 2008-07-15 Daiichi Sankyo Co Ltd Säure-additionssalze von hydropyridinderivaten
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
NZ526540A (en) * 2000-12-25 2004-11-26 Sankyo Co Medicinal compositions containing aspirin and 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine useful in preventing thrombus or embolus diseases
JP2006525328A (ja) * 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法

Also Published As

Publication number Publication date
AU2006259538A1 (en) 2006-12-28
IL187486A0 (en) 2008-06-05
US20090156632A1 (en) 2009-06-18
CA2612315A1 (en) 2006-12-28
ZA200710769B (en) 2009-09-30
EP1893205A2 (en) 2008-03-05
CN101198329A (zh) 2008-06-11
MA29722B1 (fr) 2008-09-01
TNSN07474A1 (en) 2009-03-17
KR20080016647A (ko) 2008-02-21
ECSP078014A (es) 2008-01-23
MX2007015430A (es) 2008-02-21
WO2006138317A2 (en) 2006-12-28
EP1893205A4 (en) 2010-06-30
NO20080244L (no) 2008-01-14
WO2006138317A3 (en) 2007-05-03
JP2008543853A (ja) 2008-12-04
BRPI0612624A2 (pt) 2016-11-29
EA200800075A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
ECSP078014A (es) Regimen de dosificacion para prasugrel
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
NO20081863L (no) Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
ECSP077843A (es) Tratamiento o prevención del prurito
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
CR9572A (es) Regimen de dosificacion para prasugrel
MX2020000702A (es) Composiciones solidas orales de betahistina de liberacion prolongada no pulsatil.